ALMS
Alumis Inc.Healthcare · $892M market cap
Verdict
We can't put a fair value on ALMS right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Follow ALMS
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 4, 2026: 3 open-market purchases worth $8.3M and 2 sales worth $1.0M. Why purchases matter
Purchases
AKKARAJU SRINIVAS
director · 2026-09-08
Bought
$2.9M
AKKARAJU SRINIVAS
director · 2026-09-08
Bought
$2.9M
AKKARAJU SRINIVAS
director · 2026-09-04
Bought
$2.5M
Sales
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works